Variability in morphology and cell proliferation in sequential biopsies of mantle cell lymphoma at diagnosis and relapse: Clinical correlation and insights into disease progression

Histopathology

Volumn 62, Issue 2, 2013, Pages 334-342

  Vogt, Niklas ^a   Klapper, Wolfram ^a  

^a Department of Pathology   (Germany)

Author keywords

Cytology; Growth pattern; Ki67; Relapse

Indexed keywords

CYCLIN D1; KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CELL PROLIFERATION; CELL STRUCTURE; CLINICAL ARTICLE; CYTOLOGY; DISEASE COURSE; FEMALE; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE BIOPSY; LYMPHOMA CELL; MALE; MANTLE CELL LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE PRESERVATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; GERMANY; HUMANS; KI-67 ANTIGEN; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

BLASTOIDEA;

EID: 84871103738     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12009     Document Type: Article

References (21)

1. Swerdlow SH, Campo E, Harris Net al. World Health Organization classification of tumours of the haematopoietic and lymphoid tissues. Lyon: IARC Press, 2008.
2. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat. Rev. Cancer 2007; 7; 750-762.
3. Dreyling M, Hoster E, Bea S et al. Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma (MCL): minutes of the 9th European MCL Network conference. Leuk. Lymphoma 2010; 51; 1612-1622.
4. Pott C, Hoster E, Delfau-Larue MH et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 2010; 115; 3215-3223.
5. Ott G, Kalla J, Ott MM et al. Blastoid variants of mantle cell lymphoma: frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. Blood 1997; 89; 1421-1429.
6. Tiemann M, Schrader C, Klapper W et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br. J. Haematol. 2005; 131; 29-38.
7. Determann O, Hoster E, Ott G et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2008; 111; 2385-2387.
8. Klapper W, Hoster E, Determann O et al. Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. J. Hematop. 2009; 2; 103-111.
9. Katzenberger T, Petzoldt C, Holler S et al. The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood 2006; 107; 3407.
10. Weisenburger DD, Kim H, Rappaport H. Mantle-zone lymphoma: a follicular variant of intermediate lymphocytic lymphoma. Cancer 1982; 49; 1429-1438.
11. Swerdlow SH, Habeshaw JA, Murray LJ, Dhaliwal HS, Lister TA, Stansfeld AG. Centrocytic lymphoma: a distinct clinicopathologic and immunologic entity. A multiparameter study of 18 cases at diagnosis and relapse. Am. J. Pathol. 1983; 113; 181-197.
12. Norton AJ, Matthews J, Pappa V et al. Mantle cell lymphoma: natural history defined in a serially biopsied population over a 20-year period. Ann. Oncol. 1995; 6; 249-256.
13. Royo C, Navarro A, Clot G et al. Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease. Leukemia 2012; 26; 1895-1898.
14. Carvajal-Cuenca A, Sua LF, Silva NM et al. Insitu mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. Haematologica 2012; 97; 270-278.
15. Eide MB, Liestol K, Lingjaerde OC et al. Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones. Blood 2010; 116; 1489-1497.
16. van Oers MH, Kersten MJ. Treatment strategies in advanced stage follicular lymphoma. Best Pract. Res. Clin. Haematol. 2011; 24; 187-201.
17. Klapper W. Histopathology of mantle cell lymphoma. Semin. Hematol. 2011; 48; 148-154.
18. Fu K, Weisenburger DD, Greiner TC et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 2005; 106; 4315-4321.
19. Fernandez V, Salamero O, Espinet B et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 2010; 70; 1408-1418.
20. Pott C, Schrader C, Bruggemann M et al. Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease. Eur. J. Haematol. 2005; 74; 353-358.
21. Sander B, Wallblom A, Ekroth A, Porwit A, Kimby E. Characterization of genetic changes in MCL by interphase FISH on tissue sections. Leuk. Lymphoma 2007; 48; 1344-1352.